FDA Inspection
Stason Pharmaceuticals, Inc.Stason Pharmaceuticals, Inc. – FDA Inspection, Oct 25, 2019
Record Details
This FDA Inspection record concerns Stason Pharmaceuticals, Inc., with an inspection on October 25, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Stason Pharmaceuticals, Inc.
- Inspection Date
- October 25, 2019
- Product Type
- Drugs
View Company Profile
ID · 90ef0808-a961-4985-b357-a157bccefec0
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1109969
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Enforcement
- Warning Letter
Other FDA inspections of Stason Pharmaceuticals, Inc.
11| Date | Classification | Office | Project area |
|---|---|---|---|
| April 13, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 24, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 14, 2017 | VAI | Los Angeles District Office | Generic Drug Evaluation |
| March 8, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 22, 2015 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Stason Pharmaceuticals, Inc.
- FDA Inspection 1140029 - 2021-04-13
- FDA Inspection 1067952 - 2018-08-24
- FDA Inspection 1014137 - 2017-06-14
- FDA Inspection 960658 - 2016-03-08
- FDA Inspection 911418 - 2015-01-22
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.